Marie Thibault
Stock Analyst at BTIG
(3.93)
# 555
Out of 4,843 analysts
72
Total ratings
52.94%
Success rate
9.99%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.85 | +321.05% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $10.53 | +146.91% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $325.03 | -16.93% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $162.50 | +4.62% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $34.39 | +89.01% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $105.26 | -11.65% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $67.71 | +65.41% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $34.57 | +53.31% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $85.80 | +39.86% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.18 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.43 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $16.21 | +23.38% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $140.50 | -0.36% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.84 | -21.88% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $133.58 | -6.42% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.53 | +357.52% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.91 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.52 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $196.07 | -96.94% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.85
Upside: +321.05%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $10.53
Upside: +146.91%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $325.03
Upside: -16.93%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $162.50
Upside: +4.62%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $34.39
Upside: +89.01%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $105.26
Upside: -11.65%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $67.71
Upside: +65.41%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $34.57
Upside: +53.31%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $85.80
Upside: +39.86%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.18
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.43
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $16.21
Upside: +23.38%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $140.50
Upside: -0.36%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $3.84
Upside: -21.88%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $133.58
Upside: -6.42%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.53
Upside: +357.52%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.91
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.52
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $196.07
Upside: -96.94%